The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma

Tengfei Ma, Chad C. Wiggins, Breanna Kornatowski, Raed Hailat, Andrew C. Clayburn, Winston Guo, Patrick W. Johnson, Jonathon W. Senefeld, Stephen A. Klassen, Sarah E. Baker, Katelyn A. Bruno, DeLisa Fairweather, R. Scott Wright, Rickey E. Carter, Chenxi Li, Michael J. Joyner, Nigel Paneth

Abstract

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at enrollment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.

Introduction

During the early stages of the COVID-19 pandemic, convalescent plasma (CP)—the antibody-rich plasma collected from recovered individuals—emerged as a primary therapeutic intervention. While the Mayo Clinic’s Expanded Access Program (EAP) successfully demonstrated the safety of CP, a critical knowledge gap remained regarding the granular "time course" of patient recovery. Clinicians needed to understand how quickly patients improved after transfusion and whether specific demographic or clinical factors predicted a positive response. This study sought to map the daily clinical trajectories of over 7,000 patients to identify the optimal window for CP administration.

Methods

To capture data without overburdening frontline physicians during a public health crisis, the researchers implemented the Rapid Evaluation Project (REP). This "lean" reporting sub-study utilized brief daily status updates rather than complex clinical forms.

Data Collection and Quantification

Physicians reported whether a patient’s status was "better," "worse," or "unchanged" relative to the previous day, alongside their ICU and ventilator status. These qualitative reports were converted into a 5-point ordinal scale for statistical analysis:

  • +2: Hospital discharge
  • +1: Clinical improvement (hospitalized)
  • 0: No change
  • -1: Clinical worsening
  • -2: Death

Statistical Analysis

The team employed Generalized Estimating Equations (GEE) to identify predictors of clinical improvement. Additionally, linear segmented analysis was used to determine "breakpoints"—the specific days when a patient’s recovery trajectory typically shifted or reached a plateau.

Patient Cohort and Datasets

The study analyzed data from 7,180 hospitalized patients within the Mayo Clinic EAP. The cohort was demographically diverse, with a slight overrepresentation of patients from the Midwest and West regions of the United States. At the time of transfusion, the baseline severity was high: 53% of participants were in the ICU and 28% required mechanical ventilation.

Results

The Impact of Age and Baseline Severity

Age and disease severity at the time of enrollment were the most significant predictors of clinical outcome.

  • The Age Wall: Patients aged 80 and older exhibited almost no clinical improvement following transfusion, remaining at their baseline status throughout the observation period. Compared to the 18-34 age group, patients over 80 had a significantly lower likelihood of improvement (Odds Ratio [OR] = 0.26).
  • Critical Care Limitations: While CP is often considered a "last resort," the data suggests diminishing returns for the most ill. Patients classified as "critical/end-stage" or those already on mechanical ventilation showed a steady decline in clinical status for the first two weeks post-treatment. By day 7, critical patients were 80% less likely to show improvement compared to mild/moderate cases (OR = 0.21).

Recovery Trajectories and Stabilization

The study identified a distinct "pivot point" in patient recovery. For those in the mild-to-moderate group who responded to treatment, the most rapid gains occurred within the first week, typically leveling off between days 7 and 9.

Ventilation status also dictated the speed of stabilization. Patients on ventilators did not begin to stabilize from their downward clinical course until 12–13 days post-transfusion. In contrast, unventilated patients reached a point of stabilization after only 7–8 days. Interestingly, women tended to show slightly more rapid improvement than men, provided they were not in the critical severity category at the time of treatment.

Discussion

The findings suggest a clear "window of opportunity" for the use of convalescent plasma. The plateau in improvement observed around day 9 suggests that this may be the optimal time to evaluate the need for a second dose of antibodies if recovery has stalled.

Limitations

As an Expanded Access Program, the study lacked a randomized control group. Consequently, it is impossible to definitively attribute these trajectories solely to CP, as opposed to the natural history of the disease or other standard care protocols. Furthermore, the study did not account for the specific antibody titer levels in the administered plasma, which may have influenced individual outcomes.

Conclusion

Clinical status at enrollment and patient age are the primary determinants of CP effectiveness. The data provides a pragmatic framework for triage: convalescent plasma is most effective when administered early in the disease course, before patients progress to critical respiratory failure or mechanical ventilation. For patients over 80 or those in end-stage disease, the therapeutic benefit appears significantly limited.

Summary updated

Abstract

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at enrollment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.
BibTeX
@inproceedings{ma2022role,
  author = {Tengfei Ma and Chad C. Wiggins and Breanna Kornatowski and Raed Hailat and Andrew C. Clayburn and Winston Guo and Patrick W. Johnson and Jonathon W. Senefeld and Stephen A. Klassen and Sarah E. Baker and Katelyn A. Bruno and DeLisa Fairweather and R. Scott Wright and Rickey E. Carter and Chenxi Li and Michael J. Joyner and Nigel Paneth},
  title = {{The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.707895},
}
Figure